TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07060547: Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease

Sponsor: HepQuant, LLC · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 40 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$9,408,000

Rescue Site Savings

+$6,203,400

Unlock Full NCT07060547 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07060547 Rescue Dossier →